Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CCAP Stock Forecast 2026-2027
$11.07
Current Price
$407.88M
Market Cap
Buy 4
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to CCAP Price Targets
+44.5%
To High Target of $16.00
+22.0%
To Median Target of $13.50
+8.4%
To Low Target of $12.00
CCAP Price Momentum
-4.9%
1 Week Change
-18.3%
1 Month Change
-26.5%
1 Year Change
-21.2%
Year-to-Date Change
-31.0%
From 52W High of $16.04
+1.4%
From 52W Low of $10.92
📊 TOP ANALYST CALLS
Did CCAP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Crescent Capital is one of their latest high-conviction picks.
Latest CCAP Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CCAP has a bullish consensus with a median price target of $13.50 (ranging from $12.00 to $16.00). The overall analyst rating is Buy (7.7/10). Currently trading at $11.07, the median forecast implies a 22.0% upside. This outlook is supported by 4 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mitchel Penn at Oppenheimer, projecting a 44.5% upside. Conversely, the most conservative target is provided by Finian O'Shea at Wells Fargo, suggesting a 8.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CCAP Analyst Ratings
4
Buy
3
Hold
0
Sell
CCAP Price Target Range
Low
$12.00
Average
$13.50
High
$16.00
Current: $11.07
Latest CCAP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CCAP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2026 | Ladenburg Thalmann | Christopher Nolan | Buy | Maintains | $15.00 |
| May 15, 2026 | Oppenheimer | Mitchel Penn | Perform | Downgrade | $16.00 |
| May 15, 2026 | Wells Fargo | Finian O'Shea | Equal-Weight | Maintains | $12.00 |
| Apr 16, 2026 | Keefe, Bruyette & Woods | Outperform | Maintains | $N/A | |
| Mar 30, 2026 | B. Riley Securities | Neutral | Initiates | $N/A | |
| Feb 27, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Nov 14, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Nov 14, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Nov 14, 2025 | Keefe, Bruyette & Woods | Outperform | Maintains | $N/A | |
| Sep 5, 2025 | Clear Street | Buy | Initiates | $N/A | |
| May 16, 2025 | Raymond James | Outperform | Maintains | $N/A | |
| May 16, 2025 | Keefe, Bruyette & Woods | Market Perform | Downgrade | $N/A | |
| May 16, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Apr 28, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Apr 8, 2025 | Keefe, Bruyette & Woods | Outperform | Maintains | $N/A | |
| Feb 21, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Jan 29, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Nov 25, 2024 | Keefe, Bruyette & Woods | Outperform | Maintains | $N/A | |
| Sep 30, 2024 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Aug 15, 2024 | B of A Securities | Buy | Maintains | $N/A |
Crescent Capital BDC, Inc. (CCAP) Competitors
The following stocks are similar to Crescent Capital based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CCAP
Crescent Capital
mkt cap
409.36M
Crescent Capital BDC, Inc. (CCAP) Financial Data
Crescent Capital BDC, Inc. has a market capitalization of $407.88M with a P/E ratio of 27.8x. The company generates $163.07M in trailing twelve-month revenue with a 9.3% profit margin.
Revenue growth is -10.0% quarter-over-quarter, while maintaining an operating margin of +78.6% and return on equity of +2.2%.
Valuation Metrics
Market Cap
$407.88M
Enterprise Value
$1.31B
P/E Ratio
27.8x
PEG Ratio
-0.1x
Price/Sales
2.5x
Growth & Margins
Revenue Growth (YoY)
-10.0%
Gross Margin
N/A
Operating Margin
+78.6%
Net Margin
+9.3%
EPS Growth
-295.2%
Financial Health
Cash/Price Ratio
+1.5%
Current Ratio
1.5x
Debt/Equity
134.8x
ROE
+2.2%
ROA
+4.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Crescent Capital BDC, Inc. (CCAP) Business Model
About Crescent Capital BDC, Inc.
What They Do
Provides financing solutions for middle-market companies.
Business Model
The company generates revenue by making debt investments in middle-market companies that are typically underserved by traditional banking. It provides various types of loans, including senior and subordinated debt, thereby earning income through interest and dividend payments from these investments.
Additional Information
Crescent Capital BDC, Inc. operates across diverse industries like healthcare and technology, contributing to economic growth by addressing the capital needs of businesses. Its role in the private debt market is particularly significant in the context of the post-global financial crisis, as it helps to fill funding gaps and supports entrepreneurial development.
Company Information
Sector
Financial Services
Industry
Asset Management
Employees
0
CEO
Mr. Jason A. Breaux
Country
United States
IPO Year
2020
Website
www.crescentbdc.comCrescent Capital BDC, Inc. (CCAP) Latest News & Analysis
Latest News
Quick Summary
Crescent Capital Group has closed its fourth U.S. direct lending fund, raising $10.8 billion in investable capital for lower middle market investments.
Why It Matters
Crescent's $10.8 billion fund close signals strong investor confidence in alternative credit, potentially increasing competition and opportunities in the lower middle market, influencing market dynamics.
Source: Business Wire
Market Sentiment:
Neutral
My Income Portfolio - Looking For Dividends
8 days ago
Quick Summary
Dividend investing offers steady income and potential capital appreciation, allowing investors to benefit from regular distributions while still growing portfolio value over time.
Why It Matters
Dividend investing offers steady income and potential capital appreciation, appealing to risk-averse investors while balancing growth, enhancing portfolio stability and returns.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
A leading credit team is aggressively purchasing a distressed asset class, suggesting a potential opportunity for investors to consider involvement in this market.
Why It Matters
Aggressive buying by a top credit team signals confidence in a distressed asset class, indicating potential recovery and opportunity for investors to capitalize on undervalued assets.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Crescent Capital BDC is near a 52-week low, offering a 13% yield and a 0.61x price-to-book ratio. NII covers dividends at 113.5%, though nonaccruals rose to 3.6%, primarily in healthcare.
Why It Matters
Crescent Capital BDC's 13% yield and low price-to-book ratio attract value-seeking investors, while stable NII-to-dividend coverage and active management mitigate nonaccrual risks.
Source: Seeking Alpha
Market Sentiment:
Positive
Crescent Capital BDC Q1 Earnings Call Highlights
25 days ago
Quick Summary
Crescent Capital BDC (CCAP) faced challenges in Q1, with increased non-accruals and lower earnings leading to reduced fees and a reset of the base dividend.
Why It Matters
CCAP's struggles with non-accruals and reduced earnings may signal increased risk, impacting investor confidence and potentially leading to lower stock prices and dividends.
Source: MarketBeat
Market Sentiment:
Negative
Quick Summary
Crescent Capital BDC, Inc. (CCAP) held its Q1 2026 earnings call, providing insights on financial performance and company strategies. Further details can be found in the transcript.
Why It Matters
Crescent Capital BDC's Q1 2026 earnings reveal financial performance, affecting investor sentiment, stock valuation, and potential dividend payouts, influencing investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About CCAP Stock
What is Crescent Capital BDC, Inc.'s (CCAP) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Crescent Capital BDC, Inc. (CCAP) has a median price target of $13.50. The highest price target is $16.00 and the lowest is $12.00.
Is CCAP stock a good investment in 2026?
According to current analyst ratings, CCAP has 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CCAP stock?
Wall Street analysts predict CCAP stock could reach $13.50 in the next 12 months. This represents a 22.0% increase from the current price of $11.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Crescent Capital BDC, Inc.'s business model?
The company generates revenue by making debt investments in middle-market companies that are typically underserved by traditional banking. It provides various types of loans, including senior and subordinated debt, thereby earning income through interest and dividend payments from these investments.
What is the highest forecasted price for CCAP Crescent Capital BDC, Inc.?
The highest price target for CCAP is $16.00 from Mitchel Penn at Oppenheimer, which represents a 44.5% increase from the current price of $11.07.
What is the lowest forecasted price for CCAP Crescent Capital BDC, Inc.?
The lowest price target for CCAP is $12.00 from Finian O'Shea at Wells Fargo, which represents a 8.4% increase from the current price of $11.07.
What is the overall CCAP consensus from analysts for Crescent Capital BDC, Inc.?
The overall analyst consensus for CCAP is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $13.50.
How accurate are CCAP stock price projections?
Stock price projections, including those for Crescent Capital BDC, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 11:30 AM UTC